Study Coordinators Prefer Paper COA
A recent survey by Worldwide Clinical Trials showed coordinators' are concerned eCOA interferes with normal patient rapport.
Worldwide Clinical Trials evaluated the experiences of 1,500 clinical study coordinators who use electronic clinical outcome assessment (eCOA) technologies in a global survey and found that 67% of respondents prefer paper-based assessments over eCOA solutions, with many citing concerns that these electronic solutions may interfere with the normal patient rapport that is required during the clinical assessment process. The findings highlight important considerations for the industry, with the need for easier interfaces, simplified set-up processes, and comprehensive training – all vital in improving the usability and prevalence of these technologies.
Worldwide Clinical Trials executives believe that the transition to EDC technologies, across the board, take time but understanding the users' view is important.
Read the full release.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
